Bilirubin

Overview

Bilirubin is a brownish-yellow pigment of bile formed as the final product of red blood cell (hemoglobin) breakdown, as explained in the document. It is produced mainly in the bone marrow and liver and plays an essential role in normal physiological processes. Within the normal range, it has cytoprotective and beneficial metabolic effects, particularly in protecting the liver against lipid accumulation. However, when present in excess, it becomes potentially toxic, requiring efficient detoxification and elimination mechanisms.

It is derived from heme degradation. Senescent red blood cells release heme, which is converted to biliverdin by heme oxygenase and then reduced to unconjugated bilirubin by biliverdin reductase. In the liver, unconjugated it is converted into conjugated bilirubin by the addition of glucuronic acid, making it water-soluble and suitable for excretion through bile. Measurement of it is an important laboratory tool used to assess liver function, hemolysis, biliary obstruction, and neonatal jaundice.

Symptoms

It itself does not produce symptoms; rather, symptoms arise from conditions associated with elevated levels, known as hyperbilirubinemia. According to the document, the most recognizable symptom is jaundice, characterized by yellowing of the skin and eyes.

Common symptoms include:

1. Yellow discoloration of skin and sclera
2. Dark-colored urine
3. Pale or clay-colored stools
4. Generalized itching
5. Fatigue

In neonatal jaundice, symptoms may include:

1. Yellowing starting from the face and progressing downward
2. Lethargy
3. Poor feeding
4. Dark urine and pale stools

In severe cases, particularly in newborns, excessively high unconjugated bilirubin levels can cross the blood-brain barrier, leading to kernicterus, a serious neurological condition. Adults may present with additional symptoms related to liver disease, gall bladder disorders, or hemolytic conditions.

Causes

The document explains that bilirubin elevation can occur due to increased production, impaired hepatic processing, or reduced excretion.

Major causes include:

1. Hemolytic anemia, leading to excess bilirubin production
2. Liver diseases such as hepatitis, cirrhosis, or liver injury
3. Biliary obstruction due to gallstones, tumors, or strictures
4. Infections affecting the liver or bile ducts
5. Drug-induced liver injury

Unconjugated hyperbilirubinemia occurs when bilirubin production exceeds the liver’s ability to conjugate it or when conjugation is impaired. Conjugated hyperbilirubinemia occurs when it is conjugated but cannot be excreted properly due to biliary obstruction or hepatic dysfunction. Mixed patterns may be seen in conditions affecting multiple steps of bilirubin metabolism.

Risk Factors

Risk factors for abnormal levels are related to red blood cell turnover, liver function, and bile excretion, as outlined in the document.

Key risk factors include:

1. Hemolytic disorders
2. Viral or autoimmune hepatitis
3. Chronic liver disease and cirrhosis
4. Gall bladder disease and bile duct obstruction
5. Neonatal period due to immature liver function
6. Genetic disorders affecting bilirubin metabolism

Inherited conditions such as Gilbert syndrome, Crigler-Najjar syndrome, Dubin-Johnson syndrome, and Rotor syndrome affect bilirubin uptake, conjugation, or excretion, increasing the risk of hyperbilirubinemia. Newborns are particularly vulnerable due to the physiological immaturity of hepatic enzymes.

Prevention

Abnormal levels cannot always be prevented, as they often reflect underlying physiological or pathological conditions. However, the document highlights preventive and best-practice measures aimed at early detection and complication reduction.

Preventive strategies include:

1. Early evaluation of jaundice in newborns and adults
2. Monitoring these levels in known liver or hemolytic disorders
3. Prompt investigation of pale stools or dark urine
4. Timely treatment of infections and liver disease

For accurate laboratory assessment, the document emphasizes:

1. Collection of 3.0 mL blood in a plain red-capped tube
2. Early separation of serum
3. Collection of 10 ml of urine in a sterile container when required
4. Avoidance of hemolyzed or lipemic samples, which are rejected

In neonatal jaundice, close monitoring and timely intervention, such as phototherapy or exchange transfusion, help prevent complications. Regular bilirubin assessment supports diagnosis, guides treatment decisions, and helps monitor disease progression or therapeutic response. Proper interpretation of these levels requires correlation with clinical findings and other laboratory parameters to ensure effective patient management.